April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Author Affiliations & Notes
  • Gungor Sobaci
    Vitreoretinal, GATA, Ankara, Turkey
  • Emin Ozmert
    AUTF, Ankara, Turkey
  • Ercumant Ovali
    Acibadem UTF, Istanbul, Turkey
  • Sengul Ozdek
    Gazi UTF, Ankara, Turkey
  • Gursel Yilmaz
    Baskent UTF, Ankara, Turkey
  • Gokhan Gurelik
    Gazi UTF, Ankara, Turkey
  • Hakan Durukan
    Vitreoretinal, GATA, Ankara, Turkey
  • Figen Batioglu
    AUTF, Ankara, Turkey
  • Imren Akkoyun
    Baskent UTF, Ankara, Turkey
  • Mehmet Koray Sevinc
    Vitreoretinal, GATA, Ankara, Turkey
  • Footnotes
    Commercial Relationships Gungor Sobaci, None; Emin Ozmert, None; Ercumant Ovali, None; Sengul Ozdek, None; Gursel Yilmaz, None; Gokhan Gurelik, None; Hakan Durukan, None; Figen Batioglu, None; Imren Akkoyun, None; Mehmet Koray Sevinc, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5012. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gungor Sobaci, Emin Ozmert, Ercumant Ovali, Sengul Ozdek, Gursel Yilmaz, Gokhan Gurelik, Hakan Durukan, Figen Batioglu, Imren Akkoyun, Mehmet Koray Sevinc; SUBMACULAR ALLOGENEIC ECTO-MESENCHYMAL STEM CELL TRANSPLANTATION IN RETINITIS PIGMENTOSA. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5012.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the safety and the efficacy of submacular olfactory ecto-mesenchymal stem cell (OEMSC) transplantation in patients with retinitis pigmentosa (RP).

Methods: This phase 1 clinical study approved by academic and government authorities and performed at Gulhane Military Medical Academy in Turkey includes 10 adult retinitis pigmentosa patients (2 women 8 men) with best-corrected visual acuity (BCVA) of HM to <20/200. In addition to full clinical examinations, ERG (Roland-Consult), macular OCT (Spectralis), microperimetry (MP1), and visual field examinations (Humprey 10-2; 30-2) were used for evaluation of the treatment. Using transconjuctival pars plana approach without vitrectomy in the eye with worse BCVA, OEMSCs, cultured from a single healthy adult donor, provided by GMP-certified laboratory (Acibadem-Labcell) were injected into the submacular area through 41 G needle at a dose of 2x10(6) cells/0.2ml. No topical and systemic anti-inflammatory agents were used. They were followed regularly.

Results: None showed ocular or systemic inflammatory sign and tumor development in the early period. Intravitreal membrane developed in 1 (10%) patient which was treated with vitrectomy successfully within the first month; silent epimacular membrane in 1(10%), and submacular membrane in 1(10%) were observed. OCT exams confirmed the sensory retinal detachment and placement of SCs in the submacular area within 6 hours and settlement of the cells subfoveally within a month. Five (50%) patients showed minimum 0.1log unit BCVA improvement together with patients’ satisfaction; even 1 patient (10%) with CF at 4 meter gained 20/100 vision after the first month. Central foveal thickness (CFT) increased to normal in 4 of 5 patients (80%) with low CFT. Retinal sensitivity increased 4 dB or more at locations within 10-degree in 6 (60%) patients, and central fixation improved in 5 of 7 (71%) with fixation disability, which was confirmed by patient questionnaire.

Conclusions: This novel technique with injection of allogeneic adult OEMSC into the submacular area without immunosuppression in RP patients seems to be promising for replacement/restoration of macular functions; manageable side effects, however, might be considered.

Keywords: 696 retinal degenerations: hereditary • 721 stem cells • 741 transplantation  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.